Better Context Better Decisions

Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.

$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Feb 28 | 2024Abbott and Dexcom Ads Observed; Madrigal, Esperion, Mannkind, Viatris Q4 ’23 Earnings; AZ Terminates Rights to RoxadustatPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other Feb 27 | 2024Viking Ph2 Data Impresses; Zealand Q4 ’23 Earnings Update; Know Labs Advances Non-Invasive CGM; Glucotrack Selects ManufacturerPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 26 | 2024BI/Zealand Win with Positive Ph2 MASH Data; Novo Partners with Neomorph for Drug Discovery; Modular Medical Raises $10MPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other Feb 23 | 2024Insulet Q4 ’23 Earnings; SELECT CHMP Decision in April?; Silence Achieves $10M Milestone Payment from AZPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Feb 21 | 2024Tandem Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Insulin Delivery, Other Feb 21 | 2024Novo Initiates Icosema COMBINE 4 Ph3 Trial; Eccogene Initiates Ph1 Oral GLP-1RA Study; Ionis and Teladoc Q4 ’23 EarningsPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, GLP-1RA + Basal, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Feb 20 | 2024Lilly Initiates Retatrutide T2DM Pivotal Program; Medtronic CY Q4 ’23 (FY Q3 ’24) Earnings; February CHMP Agenda; Inventiva Pauses Ph3 MASH Trial; Better Therapeutics Receives BDD for MASHPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Insulin Delivery, Other, SGLT2i Feb 15 | 2024Lilly Launches Mounjaro in the UK; Mannkind Completes INHALE-1 Enrollment; Diamyd Receives Fast Track Designation in T1DM; Alnylam Q4 ’23 EarningsPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 13 | 2024Tandem Mobi Launched in the USPurchase Blast
dexcom cover image
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Feb 08 | 2024Dexcom Q4 ’23 and FY ’23 EarningsPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, SGLT2i Feb 08 | 2024AZ and Viking Q4 ‘23 Earnings; Madrigal Publishes MAESTRO-NASH ResultsPurchase Blast
1 8 9 10 11 12 95

Get the Latest Analysis

Stay informed and aligned with frequent updates to keep a pulse on the industry.

If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.